<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03616392</url>
  </required_header>
  <id_info>
    <org_study_id>19DDI18013</org_study_id>
    <nct_id>NCT03616392</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308</brief_title>
  <official_title>A Randomized, Open-label, Multiple Dose, 2-way Crossover Study to Evaluate the Drug Drug Interaction of CKD-501 and D308 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 trial to evaluate the drug drug interaction of CKD-501 and D308
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, multiple dose, 2-way crossover study to evaluate the drug drug
      interaction of CKD-501 and D308 in healthy volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Actual">November 13, 2018</completion_date>
  <primary_completion_date type="Actual">September 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Part 1) AUCss,tau of D308</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Area under the curve of D308 at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part 1) Css,max of D308</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Max Concentration of D308 at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part 2) AUCss,tau of CKD-501</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Area under the curve of CKD-501 at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part 2) Css,max of CKD-501</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Max Concentration of CKD-501 at steady state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Part 1) Css,min of D308</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Min concentration of D308 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 1) Css,av of D308</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>average concentration of D308 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 1) Tss,max of D308</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>time of Max concentration of D308 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 1) t1/2 of D308</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>half-life time of D308</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 1) CLss/F of D308</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Apparent clearance of D308 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 1) Vdss/F of D308</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Apparent volume of distribution of D308 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 1) Fluctuation[(Css,max-Css,min)/Css,av] of D308</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Fluctuation concentration of D308 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 1) Swing[(Css,max-Css,min)/Css,min] of D308</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Swing concentration of D308 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) Css,min of CKD-501</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Min concentration of CKD-501 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) Css,av of CKD-501</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>average concentration of CKD-501 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) Tss,max of CKD-501</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>time of Max concentration of CKD-501 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) t1/2 of CKD-501</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>half-life time of CKD-501</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) CLss/F of CKD-501</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Apparent clearance of CKD-501 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) Vdss/F of CKD-501</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Apparent volume of distribution of CKD-501 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) Fluctuation[(Css,max-Css,min)/Css,av] of CKD-501</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Fluctuation concentration of CKD-501 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) Swing[(Css,max-Css,min)/Css,min] of CKD-501</measure>
    <time_frame>Day 1, 3, 4 predose(0 hour) and Day 5 predose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Swing concentration of CKD-501 at steady state</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>Part 1: Group 1(Treatment A/Treatment B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A (D308 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Group 2(Treatment B/Treatment A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment A (D308 1T)/day for 5days, QD, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Group 1(Treatment C/Treatment B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment C (CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Group 2(Treatment B/Treatment C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment C (CKD-501 1T)/day for 5days, QD, PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D308, CKD-501</intervention_name>
    <description>D308
CKD-501: Lobeglitazone sulfate 0.5mg</description>
    <arm_group_label>Part 1: Group 1(Treatment A/Treatment B)</arm_group_label>
    <arm_group_label>Part 1: Group 2(Treatment B/Treatment A)</arm_group_label>
    <arm_group_label>Part 2: Group 1(Treatment C/Treatment B)</arm_group_label>
    <arm_group_label>Part 2: Group 2(Treatment B/Treatment C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult older than 19 years at the time of screening

          2. BMI 17.5~30.5kg/m2 and body weight more than 55kg

          3. Subject who has no chronic disease within last 3 years and no symptoms or pathological
             findings

          4. Suitable subject who is determined to be suitable at the time of screening such as
             laboratory tests(hematology, blood chemistry, urinalysis, virus/bacteriological test,
             etc.), sign of vitality, electrocardiogram

          5. Subject who signed the written consent of the Chonbuk National University Hospital IRB
             to participate in this study with full understanding of the purpose and contents of
             the examination prior to the clinical trial

          6. Subject who has will and ability to participate in clinical trials

        Exclusion Criteria:

          1. Subject who has a history of clinical significant blood, kidney, endocrine,
             respiratory, gastrointestinal, urinary, cardiovascular, liver, psychiatric,
             neurological or allergic diseases(except for asymptomatic seasonal allergies not
             treated at the time of administration) or evidence(except for simple dental history
             such as dental calculus, impacted tooth, wisdom tooth, etc.)

          2. Subject with a history of gastrointestinal disorders(esophageal achalasia or esophagus
             stenosis, Crohn's disease) or gastrointestinal surgery(except for simple appendicitis
             surgery or hernia surgery or tooth extraction surgery) that may affect the absorption

          3. Clinical laboratory test results showing the following values

             * ALT or AST &gt; 2 times upper limit of normal range

          4. Subject who has a history of regular alcohol consumption exceeding 210g/week within
             6months of screening (1 glass of beer(5%)=10g, 1 glass of soju(20%)=8g, 1 glass of
             wine(12%)=12g)

          5. Those taking other clinical trial drugs or bioequivalence test drugs within 3months
             before the first administration of clinical trial drug

          6. Subject who has a systolic blood pressure of less than 100mmHg or more than 140mmHg or
             diastolic blood pressure of less than 60mmHg or more than 90mmHg of screening

          7. Subject who has significant alcohol abuse or drug abuse within a year of screening

          8. Those taking medication known to significantly induce or inhibit drug metabolizing
             enzymes within 30days prior to the first administration of clinical trial medication

          9. More than 20 smokers per day within six months of screening

         10. Those taking prescription or non-prescription drugs within 10days before the first
             administration of clinical trial medication

         11. Those who donated whole blood within 2 months or those who donated the components
             within 1 month before the first administration of the clinical trial drug

         12. Subject who has risk of serious or chronic medical, mental, or laboratory examinations
             that may increase the risk due to the administration of medicines for clinical trials
             and may interfere with the interpretation of test results

         13. Patients who are known to be hypersensitive to the drug or its components

         14. Patients with severe heart failure or heart failure(New York Heart Association(NYHA)
             Class 3, 4 heart patients)

         15. Patients with hepatic impairment

         16. Patients with a glomerular filtration rate(eGFR) less than 60ml/min/1.73m2, patients
             with end stage renal disease or dialysis

         17. Patients with diabetic ketoacidosis, diabetic coma and total coma, patients with type
             1 diabetes

         18. Before and after surgery, severe infectious patients, severe trauma patients

         19. Subjects with genetic problems such as galactose intolerance, Lapp lactase deficiency
             or glucose-galactose malabsorption

         20. Pregnant and lactating women

         21. Subject who is judged by the investigator to be ineligible to participate in the
             clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>November 15, 2018</last_update_submitted>
  <last_update_submitted_qc>November 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

